Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1).
性状
Solid
IC50 & Target[1][2]
CB2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
ClinicalTrial
参考文献
[1]. Jean-Michel Adam, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. Patent US20130116236A1.
溶解度数据
In Vitro: DMSO : 125 mg/mL (348.77 mM; Need ultrasonic)配制储备液